Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Melanoma develops as a result of several genetic alterations, with UV radiation often acting
as a mutagenic risk factor. Deep knowledge of the molecular signaling pathways of different …

Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment
strategies to overcome resistance to cancer immunotherapy are lacking,. Here we identify …

PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

Background: Tumor mutational burden (TMB) is a genomic biomarker that can predict
favorable responses to immune checkpoint inhibitors (ICIs). Although we have better …

The tumor microenvironment is overwhelmingly dictated by macrophages, intimately
affiliated with tumors, exercising pivotal roles in multiple processes, including angiogenesis …

Immune checkpoint inhibitors induce significant and durable treatment responses in about
20% of all cancers, but many patients have natural resistance to current immunotherapies …

The recent advent of targeted and immune-based therapies has revolutionized the treatment
of melanoma and transformed outcomes for patients with metastatic disease. The majority of …